The Biologics News and Reports Portal

Show Cart

All Products

Results 161 - 180 of 189

Oct 2012 Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

150.00 €

Sep 2012 Competitor Analysis: Tuberculosis Vaccines and Therapeutics

400.00 €

Aug 2012 Competitor Analysis: Malaria Vaccines & Therapeutics

300.00 €

Aug 2012 Competitor Analysis: CMV Vaccines and Therapeutics

200.00 €

Jul 2012 Competitor Analysis: Interleukin-1 (IL-1) Inhibitors and IL-1 Receptor (IL-1R) Antagonists

150.00 €

May 2012 Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics

300.00 €

Mar 2012 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

1,950.00 €

Dec 2011 Competitor Analysis: HIV Small Molecule Therapeutics

500.00 €

Nov 2011 Competitor Analysis: Anti-Infective Antibodies

400.00 €

800.00 €

(Discount: 50.00%)

Oct 2011 Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

1,920.00 €

2,400.00 €

(Discount: 20.00%)

Oct 2011 Competitor Analysis: HIV Vaccines

300.00 €

Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

1,560.00 €

1,950.00 €

(Discount: 20.00%)

Sep 2011 Competitor Analysis: Novel Mitotic Kinase Inhibitors

400.00 €

Aug 2011 Competitor Analysis: Targeted Therapy of Hepatitis C

600.00 €

Jun 2011 Competitor Analysis: Hepatitis Vaccines

350.00 €

May 2011 Competitor Analysis: Influenza Vaccines

500.00 €

Apr 2011 Competitor Analysis: Emerging Diabetes Drugs

600.00 €

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Latest Target Pipeline

STING Agonists & Antagonists

Shopping cart

Cart empty

Latest report

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Featured Products

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

All Products

Dec 2012 Competitor Analysis: Herpes Virus Vaccines and Therapeutics

Dec 2012 Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

Oct 2012 Competitor Analysis: Pneumococcal and Streptococcal Vaccines

Oct 2012 Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

Sep 2012 Competitor Analysis: Tuberculosis Vaccines and Therapeutics

Aug 2012 Competitor Analysis: Malaria Vaccines & Therapeutics

Aug 2012 Competitor Analysis: CMV Vaccines and Therapeutics

Jul 2012 Competitor Analysis: Interleukin-1 (IL-1) Inhibitors and IL-1 Receptor (IL-1R) Antagonists

May 2012 Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics

Mar 2012 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

Dec 2011 Competitor Analysis: HIV Small Molecule Therapeutics

Nov 2011 Competitor Analysis: Anti-Infective Antibodies

Oct 2011 Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

Oct 2011 Competitor Analysis: HIV Vaccines

Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

Sep 2011 Competitor Analysis: Novel Mitotic Kinase Inhibitors

Aug 2011 Competitor Analysis: Targeted Therapy of Hepatitis C

Jun 2011 Competitor Analysis: Hepatitis Vaccines

May 2011 Competitor Analysis: Influenza Vaccines

Apr 2011 Competitor Analysis: Emerging Diabetes Drugs

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing